Area of responsibility: - 132 M USD Rx business (retail & state),- Strategy for 4 product lines (hospital, respiratory, cardiological, innovative) - Team 14 FTE (team leaders, product managers, project manager, coordinator),- Portfolio/pipeline development,- P&L management to maximize CM,- Simplification of processes and procedures,- Key partners developments (key scientific specialists, commercial customers).Achievements:- Built high performing team through structure transformation and team development,- Established new processes that boosted business planning and collaboration effectiveness,- Lead development and launch of new strategy with a strong focus on customer-centricity,- Reversed portfolio performance from decline to 10% YoY growth, - Drove Rx business from #4 to #2 position on the addressable market,- Reached leadership in NPS among key therapeutic areas.

Area of responsibility: - 103 M USD HIV business (state),- Strategy and tactics for 3 products (Eviplera, Intelence, Edurant) and Vaccines launches,- Team management in a matrix structure (marketing direct reports – 4FTE; sales, commercial, finance, market access and medical affairs in dotted line),- Work in close collaboration with headquarters team (IBVT),- Development of relationships with chief specialists and government stakeholders.Achievements:- Guided customer-centric approach and remote communication integration,- Negotiated conclusion of long-term agreement with MoH,- Accomplished mature HIV portfolio growth +85% 2022 vs 2019, - Achieved #1 position in federal budget (MS 27%), #1 in regional budget (MS 41%),- Received New Employee of the year J&J Award.

Area of responsibility: - 92 M USD aesthetic products (Botox, Juvederm, CoolSculpting),- Strategic goals and framework of the AMI programme in Russia,- Tactics designed to advance HCP education and experience with Allergan products,- Team 7 FTE (AMI manager, digital manager, events manager, clinical specialists, coordinator),- Development of close collaborative relationships with national KOLs/trainers.Achievements:- Transformed structure and integrated clinical specialists’ team,- Re-launched local educational center according to international guides and best practices (was marked by Award for excellence),- Implemented new segmentation to ensure the right HCPs CJM (98% HCPs were segmented),- Rolled out AMI digital program for personalized communication with HCPs.

Area of responsibility:- 72 M USD antihypertensive portfolio (retail),- Strategy and tactics for Lozap family, Telzap family, Aprovask,- Team 3 FTE (product managers, intern),- Potential launches assessment and launch plan preparation to strengthen product portfolio (in coop. with Business Development);- Work in close collaboration with headquarters team,- Top KOLs management.Achievements:- Lead “One Sanofi” project/approach within BU Established products (ex Zentiva and Sanofi Rx),- Launched digital platform for antihypertensive products,- Launched 3 products (Telzap, Lozap AM, Telzap Plus),- Achieved Telzap leadership within INN (MS YTD’11 2018 = 38% in Vol., SU),- Re-launched Aprovasc with +72% YTD’11 2018 vs 2017,- Achieved highest SoV (27%) and Calls` effectiveness (85%) within category for Lozap AM.

Area of responsibility:- 44 M USD hypolipidemic portfolio (Retail),- Strategy and tactics for Atoris, Roxera,- Coordination of Junior product manager,- Launches preparation for new products and combinations,- KOLs development.Achievements:- Received Marketing Awards 2014, nomination: Best promotion of KRKA statins (Atoris on statins’ market #3 → #2; Roxera on rosuvastatins’ market #4 → #2),- Received Marketing Awards 2015, nomination: Best promotion of clinical trial (Roxera - ROSU-PATH).